Gene therapy in haemophilia - going for cure?

Haemophilia

Volumn 16, Issue SUPPL. 3, 2010, Pages 24-28

  Margaritis, P ^a   High, K A ^b  

^a Division of Hematology   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Animal models; Dogs; Factor VIIa; Gene therapy; Haemophilia; Mice

Indexed keywords

BLOOD CLOTTING FACTOR 7A; PARVOVIRUS VECTOR;

BLEEDING; BLOOD CLOTTING; DRUG EFFICACY; DRUG SAFETY; EXON; FIBRIN DEPOSITION; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HEMOPHILIA; HOMEOSTASIS; IMMUNE RESPONSE; LOW DRUG DOSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; SEROTYPE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; DISEASE MODELS, ANIMAL; DOGS; FACTOR VII; GENE EXPRESSION REGULATION; GENE THERAPY; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; MICE;

EID: 77953532972     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02256.x     Document Type: Review

References (13)

1. Margaritis P, Arruda VR, Aljamali M, Camire RM, Schlachterman A, High KA. Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII. J Clin Invest 2004, 113:1025-31.
2. Petersen LC, Nørby PL, Branner S. Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study. Thromb Res 2005, 116:75-85.
3. Aljamali MN, Margaritis P, Schlachterman A. Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality. J Clin Invest 2008, 118:1825-34.
4. Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie BC, Furie B. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 2004, 104:3190-7.
5. Day SM, Reeve JL, Pedersen B. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood 2005, 105:192-8.
6. Tai SJ, Herzog RW, Margaritis P. A viable mouse model of factor X deficiency provides evidence for maternal transfer of factor X. J Thromb Haemost 2008, 6:339-45.
7. Dewerchin M, Liang Z, Moons L. Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice. Thromb Haemost 2000, 83:185-90.
8. Margaritis P, Roy E, Aljamali MN. Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood 2009, 113:3682-9.
9. Russell KE, Olsen EH, Raymer RA. Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs. Blood 2003, 102:4393-8.
10. Brinkhous KM, Hedner U, Garris JB, Diness V, Read MS. Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. Proc Natl Acad Sci USA 1989, 86:1382-6.
11. Brinkhous KM, Sandberg H, Garris JB. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci USA 1985, 82:8752-6.
12. Brinkhous KM, Sigman JL, Read MS. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. Blood 1996, 88:2603-10.
13. Tranholm M, Kristensen K, Kristensen AT, Pyke C, Røjkjaer R, Persson E. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood 2003, 102:3615-20.